ArticleFEBS open bio2025
RETRACTION: Fibronectin Enhances Tumor Metastasis Through B7-H3 in Clear Cell Renal Cell Carcinoma.
Article in FEBS open bio, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Retraction of
Authors and funding
0 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
retractionJ. Xie, M. Sun, D. Zhang, C. Chen, S. Lin, and G. Zhang,"Fibronectin Enhances Tumor Metastasis Through B7-H3 in Clear Cell Renal Cell Carcinoma," FEBS Open Bio 11, no. 11 (2021): 2977-2987, https://doi.org/10.1002/2211-5463.13280. The above article, published online on 25 August 2021 in Wiley Online Library (wileyonlinelibrary.com), has been retracted by agreement between the authors; the journal Editor-in-Chief, Miguel De la Rosa; the Federation of European Biochemical Societies; and John Wiley & Sons Ltd. UK. The retraction has been agreed due to the discovery of duplications in Figures 2C and 5A. The authors originally reported these irregularities to the journal and offered corrected figures to replace the published figures. Upon the journal's analysis of the original image data, additional irregularities were found, including other image duplications with repositioning. Given the extent of the identified issues, the editors have lost confidence in the data presented and consider the conclusions of this manuscript substantially compromised. As a result, the Editor-in-Chief, FEBS Press, and John Wiley and Sons Ltd. have determined that a retraction is necessary. The authors agree with this decision.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.